Disturbed protein-protein interaction networks in metastatic melanoma are associated with worse prognosis and increased functional mutation burden

Pigment Cell and Melanoma Research

Volumn 26, Issue 5, 2013, Pages 708-722

  Schramm, Sarah Jane ^a,b   Li, Simone S ^c   Jayaswal, Vivek ^d   Fung, David C Y ^c   Campain, Anna E ^d   Pang, Chi N I ^c   Scolyer, Richard A ^a,b,e   Yang, Yee Hwa ^d   Mann, Graham J ^a,b   Wilkins, Marc R ^c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MELANOMA INSTITUTE AUSTRALIA   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Cancer systems biology; Gene expression microarray; Melanoma; Melanoma prognosis; MicroRNA; Protein protein interaction

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; TRANSCRIPTOME;

ACCURACY; ARTICLE; CANCER PROGNOSIS; GENE EXPRESSION; HUMAN; METASTATIC MELANOMA; MOLECULAR INTERACTION; MUTATION; ONCOGENE; PROTEIN PROTEIN INTERACTION;

CANCER SYSTEMS BIOLOGY; GENE EXPRESSION MICROARRAY; MELANOMA; MELANOMA PROGNOSIS; MICRORNA; PROTEIN-PROTEIN INTERACTION;

COST OF ILLNESS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; MELANOMA; MICRORNAS; MUTATION; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PROGNOSIS; PROTEIN BINDING; PROTEIN INTERACTION MAPS; REPRODUCIBILITY OF RESULTS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84882915851     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12126     Document Type: Article

References (50)

1. Ashburner, M., Ball, C.A., Blake, J.A. et al. (2000). Gene ontology: tool for the unification of biology. Nat. Genet. 25, 25-29.
2. Azuaje, F.J., Dewey, F.E., Brutsaert, D.L., Devaux, Y., Ashley, E.A., and Wagner, D.R. (2012). Systems-based approaches to cardiovascular biomarker discovery. Circ. Cardiovasc. Genet. 5, 360-367.
3. Balch, C.M., Gershenwald, J.E., Soong, S.J. et al. (2009). Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27, 6199-6206.
4. Benjamini, Y., and Hochberg, Y. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B Stat. Methodol. 57, 289-300.
5. Bogunovic, D., O'neilla, D.W., Belitskaya-Levya, I. et al. (2009). Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc. Natl Acad. Sci. USA 106, 20429-20434.
6. Breitkreutz, B.-J., Stark, C., Reguly, T. et al. (2008). The BioGRID interaction database: 2008 update. Nucleic Acids Res. 36, D637-D640.
7. Buyse, M., Loi, S., Van't Veer, L. et al. (2006). Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl Cancer Inst. 98, 1183-1192.
8. Chen, J., Sam, L., Huang, Y., Lee, Y., Li, J., Liu, Y., Xing, H.R., and Lussier, Y.A. (2010). Protein interaction network underpins concordant prognosis among heterogeneous breast cancer signatures. J. Biomed. Inform. 43, 385-396.
9. Flaherty, K.T., Robert, C., Hersey, P. et al. (2012). Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367, 107-114.
10. Fu, S.W., Chen, L., and Man, Y. (2011). miRNA biomarkers in breast cancer detection and management. J. Cancer 2, 116-122.
11. Futreal, P.A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., and Stratton, M.R. (2004). A census of human cancer genes. Nat. Rev. Cancer 4, 177-183.
12. Gerlinger, M., Rowan, A.J., Horswell, S. et al. (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892.
13. Glud, M., Klausen, M., Gniadecki, R., Rossing, M., Hastrup, N., Nielsen, F.C., and Drzewiecki, K.T. (2009). MicroRNA expression in melanocytic nevi: the usefulness of formalin-fixed, paraffin-embedded material for miRNA microarray profiling. J. Invest. Dermatol. 129, 1219-1224.
14. Gould Rothberg, B.E., and Rimm, D. (2010). Biomarkers: the useful and the not so useful - an assessment of molecular prognostic markers for cutaneous melanoma. J. Invest. Dermatol. 130, 1971-1987.
15. Gould Rothberg, B.E., Bracken, M.B., and Rimm, D.L. (2009). Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J. Natl Cancer Inst. 101, 452-474.
16. Gowrishankar, K., Snoyman, S., Pupo, G.M., Becker, T.M., Kefford, R.F., and Rizos, H. (2012). Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition. J. Invest. Dermatol. 132, 1850-1859.
17. Greenberg, E., Hershkovitz, L., Itzhaki, O. et al. (2011). Regulation of cancer aggressive features in melanoma cells by microRNAs. PLoS ONE 6, e18936.
18. Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
19. Hase, T., Tanaka, H., Suzuki, Y., Nakagawa, S., and Kitano, H. (2009). Structure of protein interaction networks and their implications on drug design. PLoS Comput. Biol. 5, e1000550.
20. Hodis, E., Watson, I.R., Kryukov, G.V. et al. (2012). A landscape of driver mutations in melanoma. Cell 150, 251-263.
21. Huang, F.W., Hodis, E., Xu, M.J., Kryukov, G.V., Chin, L., and Garraway, L.A. (2013). Highly recurrent TERT promoter mutations in human melanoma. Science 339, 957-959.
22. Ideker, T., and Krogan, N.J. (2012). Differential network biology. Mol. Syst. Biol. 8, 1-9.
23. John, T., Black, M.A., Toro, T.T., Leader, D., Gedye, C.A., Davis, I.D., Guilford, P.J., and Cebon, J.S. (2008). Predicting clinical outcome through molecular profiling in stage III melanoma. Clin. Cancer Res. 14, 5173-5180.
24. Jönsson, G., Busch, C., Knappskog, S., Geisler, J., Hrvoje, M., Ringnér, M., Lillehaug, J.R., Borg, Å., and Lønning, P.E. (2010). Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin. Cancer Res. 16, 3356-3367.
25. Keshava Prasad, T.S., Goel, R., Kandasamy, K. et al. (2009). Human protein reference database - 2009 update. Nucleic Acids Res. 37, D767-D772.
26. Kreeger, P.K., and Lauffenburger, D.A. (2010). Cancer systems biology: a network modeling perspective. Carcinogenesis 31, 2-8.
27. Lee, J.H., Choi, J.W., and Kim, Y.S. (2010). Frequencies of BRAF and NRAS mutations are different in histologic types and sites of origin of cutaneous melanoma: a meta-analysis. Br. J. Dermatol. 164, 776-784.
28. Li, J., Lenferink, A.E.G., Deng, Y., Collins, C., Cui, Q., Purisima, E.O., O'connor-Mccourt, M.D., and Wang, E. (2010). Identification of high-quality cancer prognostic markers and metastasis network modules. Nat. Commun. 1, 34.
29. Long, G.V., Menzies, A.M., Nagrial, A.M., Haydu, L.E., Hamilton, A.L., Mann, G.J., Hughes, T.M., Thompson, J.F., Scolyer, R.A., and Kefford, R.F. (2011). Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 29, 1239-1246.
30. Mann, G.J., Pupo, G.M., Campain, A.E. et al. (2013). BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J. Invest. Dermatol. 133, 509-517.
31. Mathivanan, S., Periaswamy, B., Gandhi, T., Kandasamy, K., Suresh, S., Mohmood, R., Ramachandra, Y., and Pandey, A. (2006). An evaluation of human protein-protein interaction data in the public domain. BMC Bioinformatics 7, S19.
32. McShane, L.M., Altman, D.G., Sauerbrei, W., Taube, S.E., Gion, M., and Clark, G.M. (2005). REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat. Clin. Pract. Oncol. 2, 416-422.
33. Mishra, P.J., Song, B., Mishra, P.J., Wang, Y., Humeniuk, R., Banerjee, D., Merlino, G., Ju, J., and Bertino, J.R. (2009). MiR-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism. PLoS ONE 4, e8445.
34. Muller, D.W., and Bosserhoff, A.K. (2008). Integrin β3 expression is regulated by let-7a miRNA in malignant melanoma. Oncogene 27, 6698-6706.
35. Omholt, K., Platz, A., Kanter, L., Ringborg, U., and Hansson, J. (2003). NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin. Cancer Res. 9, 6483-6488.
36. Paik, S., Shak, S., Tang, G. et al. (2004). A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817-2826.
37. Saeed, A., Sharov, V., White, J. et al. (2003). TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34, 374-378.
38. Satzger, I., Mattern, A., Kuettler, U., Weinspach, D., Voelker, B., Kapp, A., and Gutzmer, R. (2010). MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. Int. J. Cancer 126, 2553-2562.
39. Schramm, S.-J., and Mann, G.J. (2011). Melanoma prognosis: a REMARK-based systematic review and bioinformatic analysis of immunohistochemical and gene microarray studies. Mol. Cancer Ther. 10, 1520-1528.
40. Schramm, S.-J., Campain, A.E., Scolyer, R.A., Yang, Y.H., and Mann, G.J. (2012). Review and cross-validation of gene expression signatures and melanoma prognosis. J. Invest. Dermatol. 132, 274-283.
41. Segura, M.F., Belitskaya-Levy, I., Rose, A.E. et al. (2010). Melanoma microRNA signature predicts post-recurrence survival. Clin. Cancer Res. 16, 1577-1586.
42. Stark, M.S., Tyagi, S., Nancarrow, D.J., Boyle, G.M., Cook, A.L., Whiteman, D.C., Parsons, P.G., Schmidt, C., Sturm, R.A., and Hayward, N.K. (2010). Characterization of the melanoma miRNAome by deep sequencing. PLoS ONE 5, e9685.
43. Taylor, I.W., Linding, R., Warde-Farley, D., Liu, Y., Pesquita, C., Faria, D., Bull, S., Pawson, T., Morris, Q., and Wrana, J.L. (2009). Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nat. Biotechnol. 27, 199-204.
44. Thompson, J.F., Scolyer, R.A., and Kefford, R.F. (2009). Cutaneous melanoma in the era of molecular profiling. Lancet 374, 362-365.
45. Timar, J., Gyorffy, B., and Raso, E. (2010). Gene signature of the metastatic potential of cutaneous melanoma: too much for too little? Clin. Exp. Metastasis 27, 371-387.
46. Triozzi, P.L., Eng, C., and Singh, A.D. (2008). Targeted therapy for uveal melanoma. Cancer Treat. Rev. 34, 247-258.
47. Turner, B., Razick, S., Turinsky, A.L., Vlasblom, J., Crowdy, E.K., Cho, E., Morrison, K., Donaldson, I.M., and Wodak, S.J. (2010). iRefWeb: interactive analysis of consolidated protein interaction data and their supporting evidence. Database 2010, 1-15.
48. Uhlmann, S., Mannsperger, H., Zhang, J.D. et al. (2012). Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer. Mol. Syst. Biol. 8, 570.
49. Weigelt, B., Baehner, F.L., and Reis, J.S. (2010). The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J. Pathol. 220, 263-280.
50. Yao, C., Li, H., Zhou, C., Zhang, L., Zou, J., and Guo, Z. (2010). Multi-level reproducibility of signature hubs in human interactome for breast cancer metastasis. BMC Syst. Biol. 4, 151.